


Evaluating Dose Escalation of Ustekinumab in Pediatric Patients with Crohn's Disease

The effectiveness and safety of dose escalation of ustekinumab (UST) have not been investigated in children with inflammatory bowel disease



A retrospective multicenter study of children with Crohn's disease (CD) (N = 69)

Under
18

<18 years
of age



Underwent dose
escalation or
re-induction of UST



Demographic
and clinical
data collected

Three months post-UST escalation



19% discontinued therapy
due to an active disease



No serious adverse
events were recorded

UST dose escalation may be considered for favorable outcomes in children with CD

Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Pediatric Crohn's Disease (the SPEED-UP study) - A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN
Feler et al. (2022)